Quantum-Si Partners with Cell Signaling Tech to Boost Proteus PTM Analysis
Event summary
- Quantum-Si and Cell Signaling Technology (CST) announced a partnership on June 10, 2026, to advance post-translational modification (PTM) analysis on the Proteus™ platform.
- CST will provide PTM detection and immunoaffinity enrichment expertise to integrate with Quantum-Si’s Proteus workflows.
- The collaboration involves two phases: dataset generation for Proteus workflow refinement and performance benchmarking against mass spectrometry data.
- Jeff Hawkins, CEO of Quantum-Si, highlighted CST’s leadership in PTM analysis as crucial for validating Proteus’s capabilities.
The big picture
This partnership aligns with the growing demand for advanced proteomics tools that enable deeper insights into protein regulation and cell signaling. By leveraging CST’s expertise in PTM analysis, Quantum-Si aims to enhance the Proteus platform’s capabilities, potentially broadening its appeal in biomarker discovery and drug development. The collaboration underscores the strategic importance of integrating specialized knowledge in proteomics to drive innovation in life sciences research.
What we're watching
- Technology Validation
- How the integration of CST’s PTM expertise will impact the accuracy and adoption of Quantum-Si’s Proteus platform.
- Market Differentiation
- Whether Quantum-Si can position Proteus as a complementary or superior alternative to mass spectrometry in proteomics.
- Commercialization Timeline
- The pace at which Quantum-Si can commercialize Proteus with validated PTM capabilities, given the partnership’s focus on research applications.
Related topics